A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma
This study is testing a new way to treat glioblastoma, a type of aggressive brain tumor that has returned after initial treatment. Doctors want to see if adding a new drug called selinexor to the standard chemotherapy drug (temozolomide) helps shrink or stabilize tumors more effectively than chemotherapy alone.
This trial is for adults (18+) with a specific type of recurrent glioblastoma that has been confirmed through previous surgery or biopsy. Participants must have already completed initial radiation and chemotherapy and have a tumor that can be clearly measured on a scan.
You will receive either the combination therapy or the standard chemotherapy alone to compare the results. Throughout the study, you will have regular medical check-ups, MRI scans to monitor the tumor, and simple procedures to collect tissue or fluid samples for testing.
This study is currently recruiting patients at medical centers in Phoenix, Arizona, and Duarte and La Jolla, California. You should speak with your doctor to see if one of these locations is accessible for your care.
- 1Tests if a new drug combination works better than standard chemotherapy alone.
- 2Specifically for patients whose brain tumor has returned for the first time.
- 3Includes regular monitoring through MRI scans and lab tests to track your progress.
- 4Participation is strictly for those who meet specific genetic markers in their tumor.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.